HealthDay on MSN
FDA approves subcutaneous Rybrevant Faspro for EGFR-mutated non-small cell lung cancer
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback